Pharmacological treatment strategies for schizophrenia

References

• Lindenmayer JP, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology28(1), 22–31 (1995).
   Google Scholar
• Milner KK, Valenstein M. A comparison of guidelines for the treatment of schizophrenia. Psych. Ses: 53(7), 888–890 (2002).
   Google Scholar
• Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harvard Rev Psych. 9(3), 89–104 (2001).
   Google Scholar
• Kane JM, Leucht S, Carpenter D, Docherty JR Expert Consensus Guideline Series — Optimizing pharmacologic treatment of psychotic disorders. J. Clin. Psych. 64,5-19 (2003). Presents a survey of expert opinions on the pharrnacologic treatment of psychotic disorders to answer questions not explicitly addressed by research studies. The survey is used to promote a set of guidelines that includes medication selection, dosing, and dose equivalence, compliance issues, and how to characterize remission and recovery in psychotic disorders.
   Google Scholar
• Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. Psychiatry Neurosci. 28,99–112 (2003).
   PubMed Web of Science ®Google Scholar
• Van Der Weide J, Steijns LS, Van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Parmacogeneties13, 169–172 (2003).
   PubMedGoogle Scholar
• Salzman C, Solomon D, Miyawaki E et al Parental lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J. Gun. Psych. 52 (4), 177–180 (1991).
   Google Scholar
• Brooks S, Krams M, Gunn IKP and the Zirprasidone IM Study Group. The efficacy and tolerability of intramuscular ziprasidone versus intramuscular haloperidol in patients with acute, nonorganic psychosis. European Psychiatry 13(4), S303 (1998).
   PubMedGoogle Scholar
• Brooks S, Lucey JV, Gunn KD. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone intramuscular Study Group. J. Gun. Psych. 61(12), 933–941 (2000).
   Google Scholar
• Meehan K, Zhang F, David S et al. A double blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam or placebo in threatening acutely agitated patients diagnosed with bipolar mania. Gun. fiychopharmacology21, 389–397 (2001).
   Web of Science ®Google Scholar
• Donlon PT, Hopkin JT, Tupin JT et al Haloperidol for acute schizophrenic patients: an evaluation of three oral regimens. Atch. Gen. PTchiatry37, 691–695 (1980).
   PubMed Web of Science ®Google Scholar
• Casey DE, Daniel DG, Wassef AA et al Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychophalmacology28, 182–192 (2003).
   PubMed Web of Science ®Google Scholar
• Citrome LL, Daniel DG, Wassef AA, Tracy IKA, Wozniak P, Casey D. Antipsychotic monotherapy versus combination treatment with valproate in hospitalized patients with acute schizophrenia: a double blind, multicenter study. New research poster presented at the 2002 American Bychiatric Association Annual Meeting PA, USA (2002).
   Google Scholar
• Lindemayer JP, Kotsaftis A. Use of sodium valproate in violence and aggressive behaviors: a critical review. J. Gun. PTc. 6, 123–128 (2000).
   Google Scholar
• Roy A. Suicide in Schizophrenia: Suicide. Williams and Wilkins, BA, USA, 92–112 (2000).
   Google Scholar
• Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. J. Clin. Psych. 60\(Suppl. 12), 47–50 (1999).
   Google Scholar
• Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk—benefit assessment. Am. J. Psych. 152,183–190.
   Google Scholar
• Meltzer at el. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry60(7), 82–91 (2003). Suggests that clozapine therapy significantly reduces suicidal behavior. This is the first breakthrough multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine versus olanzapine and demonstrated that clozapine was associated with a lower rate of suicide attempt, hospitali7ations to prevent suicide attempts than olanzapine.
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ etal. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other disorders. J. Clin. Bychophatmacol 17,407–418 (1997).
   Google Scholar
• Tondo L, Jamison KR, Baldessarini RJ. Antisuicide effects of lithium. Ann. NY Acad. Li. 836,339–351 (1997).
   PubMed Web of Science ®Google Scholar
• Tondo L, Baldessarini RJ, Floris G, Silvetti F, Hennen J, Tohen M. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. I Clin. Psych. 59, 405–414 (1998).
   Google Scholar
• Small JG, Kellams JJ, Milstein V, Moore J. A Placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am I Psychiatry 132,1315–1317 (1975).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta- analysis of the efficacy of second-generation antipsychotics. Atch. Gen. Psychiatry 60(6), 553–564 (2003).
   Google Scholar
• •Comprehensive meta-analytical study incorporating a literature search of clinical trials between January 1953 and May 2002 of patients with schizophrenia from electronic databases, reference lists, posters, the Food and Drug Administration, and other unpublished data. The study examined 124 randomized controlled trials with efficacy data on ten second-generation antipsychotics versus first-generation antipsychotics and 18 studies of comparisons between second-generation antipsychotics. This study found that four atypical antipsychotics — dozapine, amisulpride, risperidone, and olanzapine — were superior to conventional, first-generation antipsychotic medications for the treatment of schizophrenia as measured by effect sizes.
   Google Scholar
• Volavka J. Aggression and clozapine. Poster Presented at the International Schizophmnia Research Confelynce. CO, USA (2003).
   Google Scholar
• Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotic drugs on negative symptoms in schizophrenia. I Clin. fiychopharmacology 6,329–338 (1986).
   Google Scholar
• Leucht S, McGarth J, White P et al. Carbamazepine augmentation for schizophrenia: how good is the evidence? Clin. Psych. 63,218–224 (2002).
   Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Bychiat. Sent. 49, 196–201 (1998).
   PubMed Web of Science ®Google Scholar
• Rice D. The economic impact of schizophrenia. J. Clin. Psychiatry 60 (Suppl. 1), 4–6 (1999).
   Google Scholar
• Ereshefsky L, Saldad SR, Jann MW et al. Future of depot neuroleptics therapy. Pharmacokinetic and pharmacodynamic approaches. I Clin. PTchiatry 45 (Suppl), 50–59 (1984).
   Google Scholar
• Davis JM, Matalon L, Watanabe MD et al Depot antipsychotic drugs: place intherapy. Drugs 47,741–773 (1994).
   PubMed Web of Science ®Google Scholar
• Kane JM, Aguglia E, Altamura AC et al Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacology8, 55–66 (1998).
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schiz. Bull. 23(4), 637–651 (1997).
   Google Scholar
• Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psych. 56, 29–36 (1999).
   Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H, Group at CCS. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psych. 45,789-796 (1988).
   Google Scholar
• •Describes a multicenter clinical trial to assess dozapine's efficacy in the treatment of patients who are refractory to neuroleptics. The study presents results that aid in phannacological treatment strategies for treatment-resistant schizophrenics.
   Google Scholar
• Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. fiychiatry156(7), 990–999 (1999).
   Google Scholar
• Rosenheck R, Cramer J, Xu W et al A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. N Eng. I Merl 337, 809–815 (1997).
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J. Clin. Psych. 55 (Suppl. B), 102–106 (1994).
   Google Scholar
• Spivak B, Mester R, Abesgaus J et al Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Glitz Psych. 58(7), 318–322 (1997).
   Google Scholar
• Wirshing D, Marshall B, Green M, Mintz J, Marder S, Wirshing W Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry 156,1374–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Sheitman B et al Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 159(2), 255–262 (2002).
   Google Scholar
• ••Results provide a source for treatmentguidelines indicating that clozapine and olanzapine have similar general antipsychotic efficacy and that risperidone may be somewhat less effective.
   Google Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzpaine and haloperidol for patients with treatment-resistant schizophrenia. Biol. PTchiatry 45, 403–411 (1999).
   PubMed Web of Science ®Google Scholar
• Conley RR, Tamminga CA, Bartko JJ et al Olanzapine compared with chlorpromazine in treatment resistant schizophrenia. Am. J. PTchiatry155,914–920 (1998).
   PubMed Web of Science ®Google Scholar
• Emsley R. Partial response to antipsychotic treatment: the patient with enduring symptoms. J. Clin. Psych. 60\(Suppl. 23), 10–13 (1999).
   Google Scholar
• Geodon (ziprasidone hydrochloride capsules or ziprasidone mesylate injection) Efficacy approved — special populations use in patients with schizophrenia refractory to standard therapy. Data on file (277). Pfizer Inc. (2003).
   Google Scholar
• KaneJ. Aripiprazole vs perphenazine in treatment resistant schizophrenia. New research poster: APA, Annual meeting CA, USA (2003).
   Google Scholar
• Bondolfi G, Dufour H, Patris M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry 155(4), 499–504 (1998).
   Google Scholar
• Breier A, Malhotra A, Su TP et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry 156,294–296 (1999).
   PubMed Web of Science ®Google Scholar
• Buezen JN, Birkett MA, Kiesler GM, Tollefson GD, Wood AJ, Beasley CW. Olanzapine vs. clozapine: an international double-blind study in the treatment of resistant schizophrenia. 37th ACNP Annual Meeting December 14–18, Puerto Rico (2003).
   Google Scholar
• Lindenmayer JP, Volavka J, Lieberman J et al Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. j Clin. Psychopharmacol 21 (4), 448–453 (2001).
   Google Scholar
• Conley RR, Tamminga CA, Kelly DL. Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine nonresponse. Biological PTchiatry46(1), 73–77 (1999).
   Google Scholar
• Freudenreich 0, Goff DC. Antipsychotics combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta PTchiatr Scam/. 106, 323–330 (2002).
   Google Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. I Clin. Psych. 57(9), 395–397 (1996).
   Google Scholar
• Friedman J, Ault K, Powchik P Pimozide augmentation for the treatment of schizophrenia patients who are partial responders to clozapine. Biological PTchiatry 42, 522–523 (1997).
   PubMed Web of Science ®Google Scholar
• Mowerman S, Siris S. Adjunctive loxapine in a clozapine resistant cohort of schizophrenic patients. Ann. Clin. Psych. 8(4), 193–197 (1996).
   Google Scholar
• Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am. I Psychiatry 156,145–147 (1999).
   Google Scholar
• Buchanan RVV, Kirkpatrick B, Bryant N et al Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. jPsychiatryl53, 1625–1627 (1996).
   Google Scholar
• Volavka J, Cooper TB, Czobor P et al High-dose treatment with haloperidol: the effect of dose reduction. I Clin. PTchophaimacol. 20(2), 252–256 (2000).
   PubMedGoogle Scholar
• Lindenmayer JP, Czobor P, Volavka J et al Effects of atypical antipsychotics on the syndromal profile in treatment resistant schizophrenia. J. Clin Bich. (2004) (In Press).
   Google Scholar
• Miceli JJ, Shiovitz T, Swift RII, Anziano RJ, Tensfeldt T High dose ziprasidone is associated with marginal additional QTc Increase. Program and abstracts of the American Psychiatric Association 156th Annual Meeting, May 17–22, CA, USA (2003).
   Google Scholar
• Auby P, Saha A, Ali M, Ingenito G, Wilber R, Bramer S. Safety and tolerability of aripriprazole at doses higher than 30mg. Eur. Neumpsychophaimacol 12(1003) 288 (2002).
   Google Scholar
• Csernansky JG, Mahmoud R, Brenner R et al A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng.I Med. 346(1), 16–22 (2002).
   Google Scholar
• •A well-designed double blind, prospective study for 1 year, which presents a comparison of a more effective treatment for relapse in schizophrenia. The results help to aid clinicians as the study shows that adult outpatients with clinically stable schizophrenia or schizoaffective disorder have a lower risk of relapse if they are treated with risperidone than if they are treated with haloperidol.
   Google Scholar
• Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. AIR fiychiatry154,1248–1254 (1997).
   Google Scholar
• Caroff SN, Mann SC, Campbell EC et al Movement disorders associated with atypical antipsychotic drugs. j Clin. Psych. 63\(Suppl. 4), 12–19 (2002).
   Google Scholar
• Glazer WM, Morgenstern H, Pultz JA et al Incidence of tardive dyskinesia is lower with quetiapine treatment than with typical antipsychotics in patients with schizophrenia and schizoaffective disorder. Schizophrenia Res. 41,206–207 (2000).
   Web of Science ®Google Scholar
• Hirsch SR, Kissling W Bauml J et al. A28- week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. j Clin. Psych. 63,516-523 (2002).
   Google Scholar
• Kujawa M, Sala A, Ingenito GG et al. Aripiprazole for long-term maintenance treatment of schizophrenia. Montreal, Canada: Collegium Internationale Neuropsychopharmacologicum 23rd Congress, June 23–27, (2002).
   Google Scholar
• Gupta S, Mosnik D, Black DW et al. Tardive dyskinesia: review of treatments past, present and future. Ann. Clin. Psychiatry ii, 257–266 (1999).
   Google Scholar
• Lindenmayer JP, Czobor P, Volavka J. Changes in glucose and cholesterol levels in schizophrenia patients treated with typical and atypical antipsychotics. Am PTchiatry160,290–296 (2003).
   Google Scholar
• ••One of the few prospective studies, whichrandomizes treatment assignment in patients with schizophrenia and without glycemic dyscontrol at baseline. It assesses the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in 12-week double-blind study. It found that clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels.
   Google Scholar
• Koller E, Schneider B, Bennett H, Dubitsky G. Clozapine associated diabetes. Am. Med. 111,716–723(2001).
   PubMed Web of Science ®Google Scholar
• Koller E, PM D. Olanzapine-associated diabetes mellitus. Pharmacotherapy22, 841–852 (2002).
   PubMed Web of Science ®Google Scholar
• Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int. Clin. PTchopharmacol. 16,63–64 (2001).
   PubMed Web of Science ®Google Scholar
• Koller E, Cross J, Doraiswamy P, Schneider B. Risperidone associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy23, 735–744 (2001).
   Google Scholar
• Koller E, Doraiswamy P, Cross J, Schneider B. Quetiapine associated diabetes mellitus. Presented at the 156th Annual Meeting- of the American Psychiatric Association. CA, USA (2003).
   Google Scholar
• Lindenmayer J, Nathan A-M, Smith R. Hyperglycemia associated with the use of atypical antipsychotics. j Clin. Psych. 62\(Suppl. 13), 39–44 (2001).
   Google Scholar
• Gianfrancesco F, Grogg A, Mahmoud R, Wang R-h, Nasrallah H. Differential effects of risperidone, olanzapine, clozapine and conventional antipsychotics on Type 2 diabetes: findings from a large health plan database. j Clin. Psych. 63,920-930 (2002).
   Google Scholar
• Caro J, Ward A, Carey L, Robinson K. The risk of diabetes during olanzapine use compared to risperidone use; a retrospective database analysis. j Clin. Psych. 63, 1135–1139 (2002).
   Google Scholar
• Lund B, Perry P, Brooks J, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia and hypertension. Arch. Gen. Psychiatry58, 1172–1176 (2001).
   PubMed Web of Science ®Google Scholar
• Koro C, Fedder D, Gilbert J et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipemia in schizophrenia patients. Arch. Gen. Psychiatry 59, 1021–1026 (2002).
   PubMed Web of Science ®Google Scholar
• Koro C, Fedder D, L'Italine G, Weiss S, Kreyenbuhl J. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population-based nested case-control study. BE Med. 1. 325, 243–247 (2002).
   Google Scholar
• •One of the first large-scale studies that directly quantified the association between olanzapine and diabetes by assessing a large population of patients, 19,637, who had been treated for schizophrenia during a designated period of time.
   Google Scholar
• Buse J, Cavazzoni P, Hornbuclde K, Hutchins D, Brier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. j Clin. Epidemiology 56, 164–170 (2003).
   PubMed Web of Science ®Google Scholar
• Sernyak M, Leslie D, Alarcon R, Losonczy M, Rosenheck R. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am. j PTchiatry159, 561–566 (2002).
   Google Scholar
• Citrome L, Jaffe A. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann. Pharmacother. 37, 1849–1857 (2003).
   PubMed Web of Science ®Google Scholar
• Newcomer JW, Haupt DW, Fucetola R et al Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen Psychiatry 59(4), 337–345 (2002).
   PubMed Web of Science ®Google Scholar
• Rosack J. FDA to require diabetes warning on antipsychotics. Psychiatric News 38,1 (2003).
   Google Scholar
• Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. j Clin. Psych. 62, S22—S31 (2001).
   Google Scholar
• Henderson D, Calgliero D, Gray C et al Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. Am. J. PTchiatry157, 975–981 (2000).
   PubMed Web of Science ®Google Scholar
• Melkersson K, Hulting A-L, Brismar K. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia and related psychosis. j Clin. Psych. 61,742–749 (2000).
   Google Scholar
• Meyer J. A retrospective comparison of weight, lipid and glucose changes between risperidone and olanzapine treated inpatients; metabolic outcomes at one year.J Clin. Psych. 63,425–433 (2002).
   Google Scholar
• Wirshing D, Boyd J, Meng L, Ballon J, Marder S, Wirshing W The effects of novel antipsychotics on glucose and lipid levels. Clin. Psych. 63,856–865 (2002).
   Google Scholar
• Atmaca M, M K, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. j Clin. Psych. 64,598–604 (2003)
   Google Scholar
• Koro C, Fedder D, Gilbert J et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipemia in schizophrenia patients. Arch. Gen Psych. 59,1021–1026 (2002).
   PubMed Web of Science ®Google Scholar
• Barak Y, Aizenberg D. Effects of olanzapine on lipid abnormal ties in elderly psychotic patients. Drugs Aging 20,893–896 (2002).
   Google Scholar
• Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl. 1), S5—S20 (2003).
   Google Scholar
• McGlashan TH, Miller TJ, Woods SW, Hoffman RE, Davidson L. Instrument for the assessment of prodromal symptoms and states. In: Early Intervention in Psychotic Disorders: Miller T, Mednick SA, McGlashan TH (Eds). Kluwer Academic Publishers, The Netherlands, 135–149 (2001b).
   Google Scholar
• McGorry PD, Mc Farlane C, Patton GC et al The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta PTchia. Scant/. 92, 241–249 (1995).
   PubMed Web of Science ®Google Scholar
• Comblatt B. Early pharmacotherapeutic intervention in the prodromal phase of schizophrenia: Is this a good idea? Psychotic Dis. 4(2), 3–15 (2000).
   Google Scholar
• Lieberman JA, Tollefson G, Tohen M et al HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first episode psychosis: a randomized, double blind trial of olanzapine vs haloperidol. Am. J. Psychiatry 160,1396–1404 (2003).
   Google Scholar
• Bilder RM, Goldman RS, Volavka J et al Neurocognitive effects of Clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. j Psychiatry 159(6), 1018–1028 (2002).
   PubMed Web of Science ®Google Scholar
• •The only published randomized, 12-week, double-blind study comparing effects of clozapine, risperidone, olanzapine and haloperidol on cognition.
   Google Scholar
• Green MF. Schizophrenia From a Neumcognitive Perspective. Allyn and Bacon, MA, USA (1998). loo Stroup TS, McEvoy JP, Swartz MS et al. The national institute of mental health clinical antipsychotic trials of intervention effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schiz. Bull. 29(1), 15–31 (2003).
   Google Scholar
• ••Uses a wide range of treatment settings,naturalistic design and sample sizes that are large enough to assure adequate power. The trial will aid clinicians and researchers in the administration of pharmacological treatment by establishing the long-term effectiveness and tolerability of the newer atypical antipsychotics, comparative with each other.
   Google Scholar